Author

Salmon Punekar

Institutions: NYU Langone Health, New York University

Observed institutions: NYU Langone Health, New York University

OpenAlex ID: A5133906363

Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC

2026 · Jaime Rubio-Perez, Elena Garralda, et al. · Cancer Research

Works count: 1

Citation count:

H-index:

I10-index: